"VISITORS ARE ADVISED TO ALSO CHECK OUT THE CO-RELATED ADS DISPLAYED BELOW TO HAVE ADDITIONAL KNOWLEDGE ON THE SUBJECT. YOUR SINCERE EFFORT WOULD HELP US TO SERVE YOU BETTER".

My View On Wockhardt

About The Company

One of the most renowned and fancied counter among the Health Care division.Its growth in USA has been good. It grew by 222% in the quarter backed by a 123% growth in the base US operations and the balance from Morton Grove. More than 60 products are now marketed in US. In European markets, UK leads the way with a 20% growth.

The management have serious concerns for research & development.During the quarter, the company spent Rs.13.90 crore on R&D, which was an increase on 19% on a YoY. The company for now, has postponed the demerger of R&D division into a separate unit.

About The Financials


The Company has posted results for the period ended 30th September 2008.Net revenue rose on a YoY for Q3 by 25% to Rs. 923.50 crore. Business in India grew 11% while international by 31%. Formulations grew by 26% while bulk by 11%. EBIDTA was up 17% at Rs.210.80 crore. OPM was at 22.8%. But the good story ends here. PAT was down 43% at Rs.62.20 crore. This was mainly on account of a MTM forex loss of Rs.55.30 crore. Interest outgo was also very high at Rs.48.59 crore as against Rs.26.80 crore in last Q3.

About The Stock

The stock touched a new low at Rs.100 and even now, it remains subdued at Rs.108.The stock doesn't seems to be attractive for a good investment opportunity.


Disclaimer : I do not have any personal holding in this stock.